Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy

• Status: Active, not recruiting
• Trial end date: 2024-02-20
• Target enrollment: 0
• Participant gender: All

Summary

Type 2 DM subjects having numbness, tingling and paresthesia in hands and feet (neuropathy) will be recruited. Screening of neuropathy will be done by Michigan screening instrument. This will be followed by nerve conduction studies. Specific blood parameters will also be checked. The subjects will then be divided into four treatment arms. Three groups will receive single drug and the fourth one will receive all the three drugs. These will be given for four months. Follow up will be done every month. At the end of four months, they will be assessed for any improvement in neuropathy by using Michigan neuropathy instrument and nerve conduction studies. Blood parameters will also be measured again.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Khyber Medical University Peshawar
• Treatments: Resveratrol; Superoxide Dismutase; Thioctic Acid

Criteria

Inclusion Criteria:

• Patients with Type 2 Diabetes Mellitus

• Age between 40-60 years

Exclusion Criteria:

• Malignancy

• Vitamin B12 deficiency

• History of drug or alcohol abuse

• Taking antioxidant treatment

• History and baseline investigations for renal hepatic and haematological diseases

• Pregnant or lactating women.